Thermo Fisher Beats Expectations, Market Unimpressed

Thermo Fisher Scientific exceeded expectations in Q1 2026, with $11.01 billion in sales, a 6.2% increase from last year, and $5.44 in adjusted EPS, surpassing the forecast by 3.8%. Free cash flow margin surged to 7.5%, but organic revenue only grew 1%, missing the target. Despite steady operating margin, shares fell 3.5% due to concerns about core demand in life sciences equipment. While revenue growth has slowed, analysts predict a 5.5% increase and 9.9% EPS jump over the next year. Thermo Fisher remains a player in the market, but organic growth is crucial for long-term success. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/5e0a6511147f4a80